title: [A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
abstract: A 54-year-old female was diagnosed with invasive ductal carcinoma (pT3N1M0, Stage IIIA, estrogen receptor positive [ER (+)], progesterone receptor positive [PgR (+)], human epidermal growth factor receptor type 2 [HER2] score 0) and was treated by preoperative chemotherapy with weekly paclitaxel followed by 5-fluorouracil(5-FU) plus epirubicin plus cyclophosphamide regimen(FEC). Partial mastectomy with axillary dissection was performed. The pathological examination disclosed that the tumor was scirrhous carcinoma, and a pathological partial response was achieved by chemotherapy. Multiple bone metastases were detected 18 months after the surgery during treatment with letrozole as adjuvant therapy. Retroperitoneal metastases with hydronephrosis and a lung metastasis were detected 28 months after the surgery, even though exemestane and zoledronate were administrated after detection of the bone metastases. Chemotherapy with capecitabine was started and she recovered from hydronephrosis 4 months after the start of treatment. After 32 months from the first treatment with capecitabine, the patient is presently alive without hydronephrosis due to continued chemotherapy.
authors.affiliation: Dept. of Surgical Oncology, Tokyo Medical and Dental University Graduate School, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yamauchi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Mai
authors.initials: M
authors.lastname: Kasahara
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sugimoto
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Ishiba
authors.forename: Nobuko
authors.initials: N
authors.lastname: Tamura
authors.forename: Makoto
authors.initials: M
authors.lastname: Nagahara
authors.forename: Takanobu
authors.initials: T
authors.lastname: Sato
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000556:secondary; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology*; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil